CA19‐9 Does Not Predict cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis Undergoing Liver Transplantion
Adrian Fisher, Neil D. Theise, Albert Min, Eytan Mor, Sukru Emre, Adam Pearl, Myron E. Schwartz, Charles M. Miller, Patricia A. Sheiner – 1 March 1995 – The results of liver transplantation in patients with cholangiocarcinoma have been poor. It has been suggested that elevated serum CA19‐9 levels predict cholangiocarcinoma in patients with primary sclerosing cholangitis. We analyzed the predictive value of CA19‐9 antigen as a marker of cholangiocarcinoma in patients with primary sclerosing cholangitis evaluated for liver transplantation.